{"id":"mrna1273-vaccine","safety":{"commonSideEffects":["Injection site pain","Fatigue","Headache","Myalgia","Chills","Fever","Arthralgia"],"contraindications":["Severe allergic reaction to any component of the vaccine"]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"modality":"Biologic","_dailymed":null,"mechanism":{"target":"SARS-CoV-2 spike protein","explanation":"The vaccine contains nucleoside-modified mRNA encapsulated in lipid nanoparticles. Once administered, the mRNA is taken up by cells and translated to produce the spike protein, which triggers both humoral and cellular immune responses, including neutralizing antibodies and T-cell immunity against SARS-CoV-2.","oneSentence":"Delivers mRNA encoding the SARS-CoV-2 spike protein to induce immune response and antibody production against the virus."},"_scrapedAt":"2026-03-28T01:22:11.324Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122720,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"BNT162b2","brand":"Comirnaty","company":"Pfizer/BioNTech","rationale":"mRNA vaccine for COVID-19 prevention with similar mechanism"},{"name":"Ad26.COV2.S","brand":"Jcovden","company":"Johnson & Johnson","rationale":"Viral vector COVID-19 vaccine"},{"name":"ChAdOx1 nCoV-19","brand":"Vaxzevria","company":"AstraZeneca","rationale":"Viral vector COVID-19 vaccine"},{"name":"NVX-CoV2373","brand":"Nuvaxovid","company":"Novavax","rationale":"Protein subunit COVID-19 vaccine"}],"description":"mRNA-1273 is a lipid nanoparticle-encapsulated mRNA vaccine developed by Moderna that encodes the spike protein of SARS-CoV-2. It has been widely used for prevention of COVID-19 in adults and children, with emergency use authorization and full approval in multiple countries worldwide.","indications":{"approved":[{"status":"approved","condition":"COVID-19","patientPopulation":"Adults and pediatric patients (6 months and older)"}]},"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT05436834","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-21","conditions":"SARS-CoV-2","enrollment":1807},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT04852978","phase":"PHASE2","title":"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-29","conditions":"Healthy, Chronic Stable Illness","enrollment":295},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT04649151","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-09","conditions":"SARS-CoV-2","enrollment":4328},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT06189053","phase":"","title":"A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-04-30","conditions":"Myocarditis","enrollment":1500},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT05137236","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-12-06","conditions":"SARS-CoV-2","enrollment":540},{"nctId":"NCT04930770","phase":"PHASE2","title":"Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination","status":"WITHDRAWN","sponsor":"Maria Joyera Rodríguez","startDate":"2021-09","conditions":"Covid19","enrollment":""},{"nctId":"NCT04796896","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-03-15","conditions":"SARS-CoV-2","enrollment":11942},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05160766","phase":"PHASE2","title":"Assessing Immune Response of Different COVID-19 Vaccines in Older Adults","status":"COMPLETED","sponsor":"Oliver Cornely, MD","startDate":"2021-11-08","conditions":"Prevention of COVID-19","enrollment":323},{"nctId":"NCT05197621","phase":"","title":"The Impact of COVID-19 on Maternal and Neonatal Outcomes","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-04-13","conditions":"COVID-19, Pregnancy; Infection","enrollment":300},{"nctId":"NCT05815498","phase":"PHASE3","title":"A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-28","conditions":"COVID-19","enrollment":14246},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT04854980","phase":"","title":"Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-08-03","conditions":"Covid19, Cancer","enrollment":8},{"nctId":"NCT05280158","phase":"PHASE1, PHASE2","title":"High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2022-03-10","conditions":"Lung Transplant Recipient, SARS-CoV-2, Immunosuppression","enrollment":19},{"nctId":"NCT06333704","phase":"","title":"Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-03-10","conditions":"SARS-CoV-2","enrollment":4206},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT04927065","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-05-28","conditions":"SARS-CoV-2","enrollment":5161},{"nctId":"NCT05022329","phase":"PHASE2, PHASE3","title":"COVID-19 Vaccine Boosters in Patients With CKD","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-09-30","conditions":"Chronic Kidney Diseases, COVID-19","enrollment":273},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT05228730","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).","status":"TERMINATED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":13},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT05028257","phase":"PHASE3","title":"Allergy and COVID-19 Vaccines","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-15","conditions":"Anaphylactic Reaction, Vaccine Reaction","enrollment":117},{"nctId":"NCT04922944","phase":"","title":"Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients","status":"COMPLETED","sponsor":"Huntington Memorial Hospital","startDate":"2021-03-08","conditions":"Covid19, Vaccine Reaction","enrollment":167},{"nctId":"NCT04847050","phase":"PHASE2","title":"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-28","conditions":"Solid Tumor Malignancy, Hematologic Malignancy, Leukemia","enrollment":19},{"nctId":"NCT05249829","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-02-16","conditions":"SARS-CoV-2","enrollment":3548},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05016622","phase":"PHASE2","title":"Booster Dose Trial","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-08-10","conditions":"Cancer","enrollment":106},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT04860297","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-04-16","conditions":"SARS-CoV-2","enrollment":234},{"nctId":"NCT06429020","phase":"","title":"Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy","status":"COMPLETED","sponsor":"Chimei Medical Center","startDate":"2023-01-01","conditions":"Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population","enrollment":1089},{"nctId":"NCT04715438","phase":"NA","title":"Vaccination Against COVID-19 in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2021-01-08","conditions":"Cancer","enrollment":791},{"nctId":"NCT04969250","phase":"PHASE4","title":"Vaccination for Recovered Inpatients With COVID-19 (VATICO)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-25","conditions":"Covid19","enrollment":66},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05079633","phase":"PHASE4","title":"A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-09-30","conditions":"Covid19 Vaccine","enrollment":220},{"nctId":"NCT04470427","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-07-27","conditions":"SARS-CoV-2","enrollment":30415},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT04283461","phase":"PHASE1","title":"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-16","conditions":"COVID-19, COVID-19 Immunisation","enrollment":120},{"nctId":"NCT04785144","phase":"PHASE1","title":"Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-31","conditions":"COVID-19, COVID-19 Immunisation","enrollment":135},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05894525","phase":"","title":"Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":8844},{"nctId":"NCT05894499","phase":"","title":"Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13309},{"nctId":"NCT05894590","phase":"","title":"Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13680},{"nctId":"NCT05375838","phase":"PHASE1, PHASE2","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-13","conditions":"SARS-CoV-2, Influenza","enrollment":550},{"nctId":"NCT05383560","phase":"PHASE2","title":"Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection","enrollment":179},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT06189040","phase":"PHASE4","title":"Immunogenicity After COVID-19 Vaccines in Adapted Schedules","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2021-05-26","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":580},{"nctId":"NCT05230953","phase":"PHASE3","title":"Fourth COVID-19 Vaccine Dose- mRNA1273","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2022-01-05","conditions":"COVID-19 Pandemic","enrollment":1000},{"nctId":"NCT04958304","phase":"","title":"Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2021-09-01","conditions":"SARS-CoV-2","enrollment":20},{"nctId":"NCT06006858","phase":"","title":"Post Authorization Safety Study Moderna COVID-19 Primary Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-11-03","conditions":"COVID-19","enrollment":1284},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT04811664","phase":"PHASE3","title":"A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-24","conditions":"SARS-CoV-2 Infection","enrollment":1923},{"nctId":"NCT04813796","phase":"PHASE1","title":"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-03-11","conditions":"SARS-CoV-2","enrollment":104},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04958954","phase":"","title":"Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-07","conditions":"SARS-CoV-2","enrollment":50000000},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT05420077","phase":"PHASE1","title":"Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2022-09-12","conditions":"Infectious Disease, COVID-19","enrollment":13},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT04677660","phase":"PHASE1, PHASE2","title":"A Study of TAK-919 in Healthy Japanese Adults (COVID-19)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-01-07","conditions":"Coronavirus Disease (COVID-19)","enrollment":200},{"nctId":"NCT05054218","phase":"","title":"COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-09-10","conditions":"Covid19, SARS-CoV2 Infection","enrollment":336},{"nctId":"NCT04806113","phase":"PHASE3","title":"COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-03-11","conditions":"Covid19, Rheumatic Diseases, Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05048940","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.","status":"WITHDRAWN","sponsor":"Instituto de Investigación Marqués de Valdecilla","startDate":"2021-09-01","conditions":"Covid19","enrollment":""},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05208983","phase":"","title":"SafeTy and Efficacy of Preventative CoVID Vaccines","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-05-06","conditions":"COVID-19 Virus Infection, Vaccine Response","enrollment":1286},{"nctId":"NCT04405076","phase":"PHASE2","title":"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-05-29","conditions":"SARS-CoV-2","enrollment":660},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05074368","phase":"NA","title":"Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-07-06","conditions":"Healthy Adult Volunteers","enrollment":499},{"nctId":"NCT04885907","phase":"PHASE4","title":"Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":"Vaccine Response Impaired, Immune Suppression, Covid19","enrollment":120},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04978038","phase":"PHASE4","title":"Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs","status":"UNKNOWN","sponsor":"Mark Loeb","startDate":"2022-08-01","conditions":"SARS-CoV2 Infection, Coronavirus Infection","enrollment":414}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mRNA1273 vaccine","genericName":"mRNA1273 vaccine","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}